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ABSTRACT
Propranolol is a synthetic β-adrenergic receptor-blocking drug. After oral administration, propranolol has complete and rapid gastrointestinal absorption. The bioavailability of propranolol is
approximately 25%. Propranolol may be a substrate for a distributed P-glycoprotein (P-gp), which
might lead to the efflux the drug back to the lumen of the intestine. The aim of this study was to
investigate the influence of Diltiazem as P-gp inhibitor at different concentrations on intestinal absorption of Propranolol, namely on absorption rate constant (Ka). Single Pass Intestinal Perfusion
(SPIP) technique in rats was conducted on three groups of Wistar albino rats (n=6 per group). The
first group was perfused with Propranolol HCl (75 μg/mL) alone, meanwhile the second and the
third groups were perfused with Propranolol HCl (75 μg/mL) in presence of Diltiazem HCl (250
and 1000 μg/mL) respectively. The whole small intestinal segment of anaesthetized rats was cannulated and perfused with Propranolol HCl in normal saline at 37 °C in the absence and the presence
of Diltiazem HCl. Intestinal samples were taken from outlet tubing of small intestine at different
time intervals and analyzed using a simple, rapid and validated spectrophotometric method. The Ka
values of the drug for the rats in the three groups were calculated. The mean Ka values of Propranolol HCl in the first group was 0.81±0.014 hr-1, meanwhile, Ka values of Propranolol HCl in the second and third groups (250 μg/mL and 1000 μg/mL) were 0.778±0.012 hr-1 and 0.857±0.030 hr-1
respectively. Statistically, insignificant differences were found when the three groups were compared with (P>0.05). The expected explanation for the lack effect of Diltiazem as P-gp inhibitor at
both concentrations on the absorption constant rate of Propranolol is that P-gp plays a minimal role
in the in situ intestinal absorption process of Propranolol HCl.
Keywords: Propranolol, Absorption Rate Constant, Diltiazem, P-Glycoprotein.
† This paper was extracted from a master's thesis in pharmacy by student Hannan Fayyad entitled " The Effect of Diltiazem on Propranolol Absorption by Using in situ Single-Pass Intestinal Perfusion Technique in
Rats ", which was defended on 03/07/2017.

INTRODUCTION
β-blockers have been used for a tremendous array of indications such as the treatment of hypertension, angina pectoris, and
cardiac arrhythmias, as well as for a number
of other indications including migraine, hyperthyroidism and tremors [1].
According to the Biopharmaceutical
Classification System (BCS), the drug absorption is classified on the basis of solubility
and membrane permeability [2]. P-gp, multidrug resistance protein 1 (MDR1), is an efflux transporter which is expressed in different barriers such as intestine, liver, kidneys,

brain, testis, placenta and lung and it is also
found in ocular tissue [3-5]. P-gp is the major
efflux transporter protein, responsible for
reduced absorption of many drugs [6].
Propranolol, a β-blocker drug, is considered one of characterized P-gp substrate [79]. Propranolol was the first prototype drug
for β-blockers and it is still used over the
world [1]. Propranolol pharmacokinetics
have been studied quite extensively [10]. The
possibility of Propranolol transport by P-gp
in intestine playing a significant role in its
pharmacokinetics by extruding it from their
intended site of action [7].
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Absorption is a complex kinetics process
that is dependent on many physiological,
physicochemical and dosage form factors. Ho
and co-authors announced that, the absorption characteristics of a drug are determined
by the physicochemical properties of the drug
as well as by the bio-physicochemical properties of the gastrointestinal barrier membrane [11].
Limited drug delivery to the systemic
circulation which is a common cause of decreased absorption of Propranolol, may be
due to the over expression of adenosine triphosphate (ATP)-driven drug efflux pumps at
the intestine barrier like P-gp.
Specific inhibition of P-gp with verapamil significantly improves the absorption
of Propranolol; therefore, Propranolol combination with P-gp inhibitors may be a promising therapeutic strategy to improve the gastrointestinal drugs absorption [12].
Several well-established methods are
available to determine Ka, among these
methods, as Single Pass Intestinal Perfusion
(SPIP) technique. The in-situ rat intestinal
perfusion technique is a commonly used for
the assessment of permeability of drugs, Ka
and the functional role of permeability (P-gp)
on kinetics of drug transport through the
whole intestine [13-15].
Diltiazem was identified as P-gp inhibitor, which could be setting off an opportunity
in improving absorption of P-gp substrate by
inhibiting P-gp in intestine [16].
The objective of present research study
is to investigate the influence of Diltiazem as
P-gp inhibitor at different concentrations on
the intestinal absorption of Propranolol,
namely on absorption rate constant.
MATERIALS AND METHODS
Chemicals and Instrumentation
Propranolol HCl and Diltiazem HCl
standards were purchased from SigmaAldrich Company. Normal saline (0.9 % w/v)
was obtained from B. Braun Melsungen AG
(Germany). Thiopental sodium (500 mg vial)
was obtained from Rotex medica (Germany).
Shimadzu double beam UV-VIS spectrophotometer (UV-1601) was used. Centrifugation

was made with Kokusan (H-103N) Series
Centrifuge.
Animals and Study Design
Eighteen healthy Wistar albino male rats
(weighted: 250-300 g, 7-9 weeks aged) were
purchased from Center of Experimental Animals, Harlan Laboratories (Jerusalem). Animals were housed 4 per cage in an airconditioned room under constant temperature
(22 ± 2℃) with free access to food and
drinking water [17]. Rats were maintained on
a 12 h light-dark cycle [18]. The normal life
conditions for the animals were kept based on
the International Animal Ethics Committee.
All experiments with rats were conducted
according to the Canadian guide for the use
of laboratory animals [19].
An in-situ intestinal perfusion procedures were performed in rats according to the
methods described previously [20-22]. Rats
had been fasted for 12-18 h before experiment with free access to water (Ad Lipitum).
Then they were anaesthetized by administration of an intraperitoneal thiopental (50
mg/kg). Anaesthetized rats were placed on
the fixing plate under a heating lamp keeping
a normal body temperature (37 oC) of the rats
during all experiments. The surgical procedure was initialized by a midline abdominal
incision of approximately 10 cm to expose
small intestine and, then two L-shaped cannulas were inserted carefully through small
narrow open at the initiate of duodenum and
end of ileum. The cannulas were secured by
ligation with silk suture and the biliary duct
was also ligated. Then, the small intestine
was returned to abdominal cavity to maintain
its integrity. The intestinal lumen was rinsed
using a syringe containing normal saline
(37oC) that pumped slowly through the gut
via the inlet duodenum cannula and out the
ileal cannula until the effluent solution was
clear and free of feces. After cleaning the
intestine, the remaining perfused solution
was expelled from the intestine by air
pumped via syringe and 10 mL of drug solution was immediately introduced into the
small intestine segment by the syringe. In the
first group 10 mL prepared solution, containing Propranolol alone at concentration (75
µg/mL) in normal saline (0.9% w/v) was perfused into small intestine segment of six rats.
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The second and third groups of rats were perfused with 10 mL solution containing Propranolol (75 µg/mL) in combination with
Diltiazem (250, 1000 µg/mL) respectively.
The surgical area was covered with a wet
cotton pad, and drops of normal saline (37oC)
were added to the cotton to prevent disturbing the circulatory system and dryness of intestine.
Perfused samples (300 µL) were collected from both sides alternatively, each 5
minutes for a total of 30 minutes. The collected samples were transferred into 2 mL
Eppendorf tubes, centrifuged at 5000 rpm for
10 minutes and then, Propranolol concentrations were determined spectrophotometically
on the same day.
Analytical procedures
200 µL of the collected supernatant were
transferred and diluted to 3 mL with normal
saline. Subsequently, the absorbance was
measured at 319 nm against blank and then
the concentration of each sample was determined using calibration curve to determine
Ka of Propranolol. The samples were taken in
triplicate. The spectrophotometric method
used for analysis of Propranolol in intestinal
fluid samples was validated for specificity,
linearity, precision, accuracy, and stability by
previous study carried out by Abushammala
and collaborators [12].
Pharmacokinetic Analysis
Intestinal absorption of Propranolol was
evaluated using its apparent first-order rate
constant kap calculated according to the following equation:
lnCt = lnC0 – kap . t
Ct: Concentration of drug after t time of
perfusion, Co: Initial drug concentration, kap:
Apparent absorption rate constant and t:
Time.
Statistical Analysis
The data obtained were treated and analyzed by using Statistical Package of Social
Science (SPSS) program (Version 22). Oneway ANOVA and Duncan tests were applied
in this study. Results were assumed to be statistically significant with a P-value < 0.05.

RESULTS AND DISCUSSION
The absorption of orally administered
Propranolol is essentially complete in the
intestine with no intestinal metabolism [23].
Although, the physiological role of P-gp is
still not fully cleared, the function of this efflux transporter in pharmacokinetics is highly
appreciated. P-gp can minimize the absorption of orally administered drugs and reduce
bioavailability [24-26], but co-administration
of P-gp inhibitors such as verapamil, nifedipine, and diltiazem can enhance bioavailability of many drugs by inhibiting P-gp efflux
activity [24, 27]. In the present study, Propranolol was selected as an example of a Pgp substrate with limited oral bioavailability
[7-9]. By co-administration of Propranolol
with Diltiazem at two different concentrations, we sought to increase Propranolol bioavailability by pass P-gp mediated secretory
efflux, thereby increasing its absorptive drug
transport. Diltiazem was chosen for P-gp inhibition because it has been observed to effectively inhibit efflux activity [27]. The
first-generation inhibitor, Diltiazem, has successfully antagonized P-gp efflux activity
both in- vitro and in-vivo [3].
The analysis of Propranolol in intestinal
luminal fluids collected from rats was performed using direct spectrophotometric assay
of collected intestinal fluid samples at λmax =
319 nm. At the selected wavelength, no interferences from intestinal components or Diltiazem HCl were recorded since the λmax of
Diltiazem HCl is far away from that of Propranolol HCl (Diltiazem HCl showed zero
absorbance at 319 nm). Furthermore, a linear
relationship between concentration and absorbance of Propranolol HCl, at 319 nm, was
established over a concentration range of 1075 µg/mL (R2 = 0.999) and the limits of detection (LOD) and quantification (LOQ) were
1.0 and 5.0 μg/mL, respectively. The measured concentrations of Propranolol HCl, as
shown in table 1, were within the range of
linearity of the validated calibration curve.
According to our obtained results the
means of ln remnant concentrations of Propranolol from the three groups after intestinal
perfusion of Propranolol (75 μg/mL) alone or
in combination with Diltiazem at both concentrations (250 and 1000 μg/mL) showed a
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low inter-individual variation and are reprefigure 1.
sented in table 1 and graphically shown in
Table (1): The mean of ln remnant concentrations of data obtained experimentally for the three
groups.
Time (min)

Propranolol HCl alone

With (250 µg/mL) Diltiazem HCl

With (1000 µg/mL) Diltiazem HCl

0.0

4.305±0.04

4.304±0.08

4.303±0.03

5.0

4.141±0.05

4.149±0.05

4.139±0.05

10.0

4.098±0.07

4.071±0.06

4.063±0.06

15.0

4.026±0.06

4.012±0.04

3.991±0.06

20.0

3.933±0.05

3.922±0.07

3.926±0.05

25.0

3.893±0.06

3.890±0.06

3.843±0.04

30.0

3.810±0.07

3.822±0.05

3.790±0.05

Mean of ln rem nant concentrations (µg/m L)

4.3
Variable
Propranolol HCl alone
With (250 µg/mL) Diltiazem HCl
With (1000 µg/mL) Diltiazem HCl

4.2

4.1

4.0

3.9

3.8

3.7
0

5

10

15

20

25

30

Tim e (Min)

Figure (1): Graphical representation of the fit of the apparent first-order equation to the obtained
mean data (remaining luminal concentrations for the three groups).
HCl (75 µg/mL) co-perfused with Diltiazem
The Ka mean values of Propranolol HCl
HCl (250 and 1000 µg/mL) were
(75 μg/mL) perfused alone in intestine using
0.778±0.012 hr-1 and 0.857±0.030 hr-1 reSPIP in rats was 0.81±0.014 hr-1. The gradual
spectively, suggesting that P-gp plays a mindecrease of remnant Propranolol concentraimal role in the in-situ intestinal absorption
tions throughout time indicates that Proprocess of Propranolol with high water solupranolol absorption followed first order kibility and high membrane permeability (table
netic. It was demonstrated that, absorption
2).
rate constant mean values Ka of Propranolol
Table (2): Calculated parameters of Propranolol in the three groups.
With (250 µg/mL) Diltiazem HCl

With (1000 µg/mL)
Diltiazem HCl

Calculated parameters

Propranolol HCl alone

ka (hr-1)

0.81±0.014

0.778±0.012

0.857±0.030

A0 %

96.19±0.006

97.11±0.016

96.19±0.015

R

0.968±0.034

0.987±0.006

0.985±0.023

ka: Absorption rate constant, Ao%: Estimated inclination of the absorption line, R: coefficient of correlation.
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The statistical evaluation of the data is
shown in table 3 and represents the results of the
statistical significance of homogeneity within
each group of the three groups (Duncan test) and

results of one-way ANOVA between the three
groups with statistical significance level when (P<
0.05).

Table (3): shows the results of statistical evaluation of the data obtained experimentally after the application
of a parametric test (Duncan test) to evaluate the homogeneity within each group of the three groups and the
One-way ANOVA test. (P>0.05).
One-way ANORat groups
Number of rats
F-value
Duncan test
VA test
First group
6
1.023
0.422
Second group
6
1.198
0.334
0.693
Third group
6
0.693
0.633
sorption process of Propranolol. Further, clinical
A validated spectrophotometric method was
studies must be conducted to confirm the obtained
used for intestinal fluid samples analysis. The
results.
absorbance of Propranolol HCl was measured at
ƛmax 319 nm, without any interferences from DilACKNOWLEDGMENT
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